Valiltramiprosate
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jan 31, 2026 (NCT07284472)
Timeline
2020s
- Jan 1, 2026
Earliest Phase 2 Sponsor(trial)
Mechanism of action
APLP1 inhibitor
- Beta amyloid A4 proteinSTABILISER
Beta amyloid A4 protein stabiliser
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@H](N)C(=O)NCCCS(=O)(=O)O- Mol. weight
- 238.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL4650301 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07284472 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2026 | Exciva GmbH |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exciva GmbH | For profit | 1 | 1 | 1 | 2026 |
1 organizations
Page 1 / 1